恶性胸水的过继免疫治疗

Adoptive Immunotherapy for Malignant Pleural Effusion

应用淋巴因子激活的杀伤细胞（ＬＡＫ细胞），肿瘤浸润淋巴细胞（ＴＩＬ细胞）联合过继免疫疗法（ＡＩＴ）治疗恶性胸水１０例。其中肺癌伴胸膜转移８例，胃癌和食管癌术后胸膜转移各１例。经ＬＡＫ细胞，ＴＩＬ细胞及白细胞介素Ⅱ治疗后显示，８例病人在治疗后２～４周胸水完全消失，１例明显减少，自觉症状均有明显改善。作者探讨了过继免疫治疗的疗效与效应细胞扩增倍数、扩增培养时间和活性的关系，认为应用过继免疫疗法治疗恶性胸水是可行的。

Ten patients with malignant pleural effusin (MPE)were treated with adoptivei immunotherapy(AIT),consist-ing of IL-2,LAK and TIL of patients. Among them 8 cases were lung cancer with metastais to the pleura,one was gastriccancer and another one was esophageal cancer,The results showed that the MPE disappeared completely in 8 patients and re-duced greatly in one patient 2～4 weeks after treatment.All patients felt well after the therapy. The relation between the cu-rative effect of the AIT and the reproductive rate,culture time and activity of the effector cells was discussed. The authorssuggest that AIT is feasible in the treatment of MPE.